Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Netherlands
Clinical trial register · European Union · CTIS

Clinical Trials in Netherlands, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2556 most recently authorised of 12777 total CTIS records — a stated recency window, not the full historical archive. Synced 06 Nov 2026, 03:17 UTC
2556
Shown in this register
most recently authorised
12,777
Total on CTIS
full historical archive
789
Phase III
within the shown window
Top member states
Spain 1075 France 930 Germany 898 Italy 778 Poland 619 Netherlands 547
Narrow the registerReset
Phase
Phase I 566 Phase I/II 228 Phase II 721 Phase III 789 Phase IV 252
Lead sponsor
AstraZeneca AB 65 Merck Sharp & Dohme LLC 51 Pfizer Inc. 50 Assistance Publique Hopitaux De Paris 49 Novartis Pharma AG 47
Member state
Spain 1075 France 930 Germany 898 Italy 778 Poland 619 Netherlands 547 Belgium 455 Czechia 341
All 28 states

Trials with a site in Netherlands

97 of 2556 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
Mass Balance and Absolute Bioavailability of [14C]-VH4011499
2026-527050-40-00Human immunodeficiency virus (HIV) infections
Viiv Healthcare UK Limited
Virus Diseases
Netherlands
05/11/2026
Phase I
Merck Sharp & Dohme LLC
Neoplasms
Netherlands
03/11/2026
Phase I
Radboud universitair medisch centrum Stichting
Bacterial Infections and Mycoses
Netherlands
03/11/2026
Phase I
Argenx
Nervous System Diseases
Slovenia, Latvia, Denmark, Germany, Belgium, Norway, Spain, Poland, Lithuania, Italy, France, Netherlands
27/10/2026
Phase I
Nadeno Nanoscience AS
Neoplasms
Netherlands
16/10/2026
Phase I
Amsterdam UMC Stichting
Neoplasms
Netherlands
09/10/2026
Phase I
Nimbus Salacia Inc.
Immune System Diseases
Netherlands
30/09/2026
Phase I
UCB Biopharma
Immune system processes
Greece, Italy, Netherlands, Austria, Belgium, Sweden, Spain, Denmark, Germany
28/09/2026
Phase I
Universitair Medisch Centrum Groningen
Nervous System Diseases
Netherlands
28/09/2026
Phase I
Drug-drug interaction study of midazolam and brensocatib
2026-526670-16-00Non-Cystic Fibrosis Bronchiectasis
Insmed Inc.
Respiratory Tract Diseases
Netherlands
28/09/2026
Phase I
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Netherlands
24/09/2026
Phase I
Eli Lilly & Co.
Nervous System Diseases
Netherlands, Belgium, Germany, Spain
22/09/2026
Phase I
Basilea Pharmaceutica International AG Allschwil
Not possible to specify
Netherlands
21/09/2026
Phase I
Novartis Pharma AG
Neoplasms
Germany, France, Netherlands, Spain, Italy
15/09/2026
Phase I
Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)
2025-521143-20-00Bone Morphogenic Protein Receptor type 2 mutation carriers …
Amsterdam UMC Stichting
Diagnosis
Netherlands
10/09/2026
Phase I
F. Hoffmann-La Roche AG
Neoplasms
Spain, Poland, Romania, Hungary, Germany, Italy, Belgium, Netherlands, Denmark, France
07/09/2026
Phase I
A Phase 1 study of a novel sublingual insulin formulation
2025-521863-11-00Type 1 diabetes mellitus
Sublin B.V.
Metabolism
Netherlands
04/09/2026
Phase I
Novo Nordisk A/S
Not possible to specify
Netherlands
21/08/2026
Phase I
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Nervous System Diseases
Netherlands
21/08/2026
Phase I
Exelixis Inc.
Neoplasms
Italy, Netherlands, France, Spain
11/08/2026
Phase I
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
2025-522532-14-00Advanced solid tumors
Pfizer Inc.
Neoplasms
Netherlands, France, Spain
11/08/2026
Phase I
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Pathological Conditions, Signs and Symptoms
Netherlands
30/07/2026
Phase I
Nav 1.8 and 1.7 combo trial
2026-526867-39-00Pain
Niroda Therapeutics Inc.
Nervous System Diseases
Netherlands
30/07/2026
Phase I
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands
21/07/2026
Phase I
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)
2025-521887-37-00Ovarian Neoplasms Breast Neoplasms Pancreatic Intraductal N…
Eli Lilly & Co.
Neoplasms
Germany, Netherlands
07/07/2026
Phase I
Stichting Radboud University Medical Center
Neoplasms
Netherlands
02/07/2026
Phase I
Zealand Pharma A/S
Skin and Connective Tissue Diseases
Netherlands
01/07/2026
Phase I
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
Belgium, Netherlands, Spain, Germany, Italy
01/07/2026
Phase I
Boehringer Ingelheim International GmbH
Not possible to specify
Netherlands
30/06/2026
Phase I
Three-part PK and PD study of AXN-027
2025-524019-35-00Chronic pain, refractory epilepsy, and other neurological d…
Axonis Therapeutics Inc.
Nervous System Diseases
Netherlands
26/06/2026
Phase I
Novo Nordisk A/S
Not possible to specify
Netherlands
19/06/2026
Phase I
Arcus Biosciences Inc.
Skin and Connective Tissue Diseases
Netherlands
16/06/2026
Phase I
Bayer Consumer Care AG
Neoplasms
Finland, Spain, Sweden, Italy, Denmark, Netherlands, Belgium
08/06/2026
Phase I
T cell imaging in kidney transplantation (TIK)
2025-522490-11-00Renal allograft rejection
Radboud universitair medisch centrum Stichting
Immune system processes
Netherlands
04/06/2026
Phase I
GRAIN, Prospective Pilot Study
2025-524470-41-00Esophageal dysplasia, Barrett's esophagus, Esophageal adeno…
Universitair Medisch Centrum Groningen
Neoplasms
Netherlands
01/06/2026
Phase I
Galapagos
Not possible to specify
Netherlands
22/05/2026
Phase I
150 mg CIT-013 phase 1 trial
2026-526153-34-00Immune mediated inflammatory diseases
Citryll B.V.
Immune System Diseases
Netherlands
22/05/2026
Phase I
Dianosic
Respiratory Tract Diseases
Netherlands
21/05/2026
Phase I
SAR447971 first-in-human study
2026-525333-22-00Hidradenitis
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Netherlands
20/05/2026
Phase I
Mission Therapeutics Limited
Nervous System Diseases
Germany, Netherlands, France
18/05/2026
Phase I
Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184
2026-525590-40-00human immunodeficiency virus (HIV)
Viiv Healthcare UK Limited
Immune System Diseases
Netherlands
18/05/2026
Phase I
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Netherlands
15/05/2026
Phase I
Corteria Pharmaceuticals
Cardiovascular Diseases
Netherlands
13/05/2026
Phase I
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Denmark
11/05/2026
Phase I
Glaxosmithkline Research & Development Limited
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Netherlands
06/05/2026
Phase I
InflaRx GmbH
Not possible to specify
Netherlands
01/05/2026
Phase I
Klear Bio Inc.
Immune System Diseases
Netherlands
30/04/2026
Phase I
Centauri Therapeutics Limited
Bacterial Infections and Mycoses
Netherlands
30/04/2026
Phase I
Oryzon Genomics S.A.
Not possible to specify
Netherlands
30/04/2026
Phase I
Neurocrine Biosciences Inc.
Nervous System Diseases
Netherlands
29/04/2026
Phase I
A Phase 1 Study of AIR-001 in Adults with AATD.
2025-523558-14-00Alpha-1 Antitrypsin Deficiency
Airna Corp.
Respiratory Tract Diseases
Sweden, Ireland, Spain, Netherlands, Portugal, Germany
17/04/2026
Phase I
A trial comparing how the body absorbs and gets rid of petadeferitrin taken as two different forms in healthy people
2025-525025-12-00Iron overload from thalassemia, transfusion-dependent myelo…
Pharmacosmos A/S
Hemic and Lymphatic Diseases
Netherlands
07/04/2026
Phase I
Mironid Limited
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Netherlands
01/04/2026
Phase I
Verve Therapeutics Inc.
Cardiovascular Diseases
Netherlands
30/03/2026
Phase I
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands
16/03/2026
Phase I
CRISPR Therapeutics AG
Hemic and Lymphatic Diseases
Spain, Germany, France, Denmark, Italy, Netherlands
12/03/2026
Phase I
F. Hoffmann-La Roche AG
Population Characteristics
Netherlands
11/03/2026
Phase I
F. Hoffmann-La Roche AG
Cardiovascular Diseases
Netherlands
06/03/2026
Phase I
Novartis Pharma AG
Not possible to specify
Netherlands
06/03/2026
Phase I
Lycia Therapeutics Inc.
Immune System Diseases
Netherlands
06/03/2026
Phase I
Tenvie Therapeutics Inc.
Musculoskeletal and Neural Physiological Phenomena
Netherlands
24/02/2026
Phase I
Denali Therapeutics Inc.
Nervous System Diseases
Netherlands
18/02/2026
Phase I
F. Hoffmann-La Roche AG
Population Characteristics
Netherlands
11/02/2026
Phase I
Alnylam Pharmaceuticals Inc.
Nervous System Diseases
Spain, Netherlands
10/02/2026
Phase I
Dompe' Farmaceutici S.p.A.
Eye Diseases
Netherlands
09/02/2026
Phase I
Basilea Pharmaceutica International AG Allschwil
Bacterial Infections and Mycoses
Netherlands
06/02/2026
Phase I
Almirall S.A.
Immune System Diseases
Netherlands
06/02/2026
Phase I
CimCure B.V.
Neoplasms
Netherlands
29/01/2026
Phase I
A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants
2025-524310-28-00Epilepsy, amotrophic lateral sclerosis, neuropathy
Quralis Corp.
Nervous System Diseases
Netherlands
23/01/2026
Phase I
AC Immune S.A.
Nutritional and Metabolic Diseases
Netherlands
13/01/2026
Phase I
Arvinas Operations Inc.
Nervous System Diseases
Netherlands
24/12/2025
Phase I
Janssen Cilag International
Immune System Diseases
Netherlands
22/12/2025
Phase I
Immunic AG
Nervous System Diseases
Netherlands
17/12/2025
Phase I
Boehringer Ingelheim International GmbH
Not possible to specify
Netherlands
12/12/2025
Phase I
Boehringer Ingelheim International GmbH
Not possible to specify
Netherlands
10/12/2025
Phase I
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands
09/12/2025
Phase I
Prinses Maxima Centrum voor Kinderoncologie B.V.
Neoplasms
Netherlands
08/12/2025
Phase I
First-in-Human Study of RO7812653
2025-522101-37-00Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitiv…
F. Hoffmann-La Roche AG
Nervous System Diseases
Sweden, Poland, Spain, Netherlands
02/12/2025
Phase I
Genentech Inc.
Nutritional and Metabolic Diseases
Netherlands
01/12/2025
Phase I
Genentech Inc.
Nutritional and Metabolic Diseases
Netherlands
26/11/2025
Phase I
Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS
2025-523872-22-00Parkinsons's Disease and amyotrophic lateral sclerosis (ALS)
Nrg Therapeutics Limited
Nervous System Diseases
Netherlands
17/11/2025
Phase I
Regeneron Pharmaceuticals Inc.
Nervous System Diseases
Netherlands, Belgium
17/11/2025
Phase I
The effect of SYX-5219 on an immune response in the skin.
2025-522217-27-00Atopic dermatitis (AD)
Sitryx Therapeutics Limited
Skin and Connective Tissue Diseases
Netherlands
14/11/2025
Phase I
Arvinas Operations Inc.
Nervous System Diseases
Netherlands
14/11/2025
Phase I
Boehringer Ingelheim International GmbH
Neoplasms
Belgium, Netherlands
14/11/2025
Phase I
F. Hoffmann-La Roche AG
Population Characteristics
Netherlands
07/11/2025
Phase I
A trial to evaluate the absolute bioavailability of cenerimod in healthy male participants
2025-522320-27-00Not applicable - healthy volunteer trial
Viatris Innovation GmbH
Not possible to specify
Netherlands
07/11/2025
Phase I
AstraZeneca AB
Cardiovascular Diseases
Netherlands
03/11/2025
Phase I
A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults
2025-522930-29-00Incomplete Response - Major Depressive Disorder (IR-MDD)
Otsuka Pharmaceutical Development & Commercialization Inc.
Mental Disorders
Netherlands
31/10/2025
Phase I
Amgen Inc.
Neoplasms
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium
28/10/2025
Phase I
Vertero Therapeutics Inc.
Nervous System Diseases
Netherlands
27/10/2025
Phase I
Springworks Therapeutics Inc.
Skin and Connective Tissue Diseases
Netherlands
22/10/2025
Phase I
Dompe' Farmaceutici S.p.A.
Pathological Conditions, Signs and Symptoms
Netherlands
17/10/2025
Phase I
Amsterdam UMC Stichting
Neoplasms
Netherlands
15/10/2025
Phase I
ProQR Therapeutics VIII B.V.
Nutritional and Metabolic Diseases
Netherlands
14/10/2025
Phase I
Triveni Bio Inc.
Skin and Connective Tissue Diseases
Netherlands
07/10/2025
Phase I
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)
2025-521315-39-00Axial spondyloarthritis
Grey Wolf Therapeutics Limited
Hemic and Lymphatic Diseases
Belgium, Germany, Netherlands, Spain, Poland
06/10/2025
Rows per page Showing 1–97 of 97
1
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 6 November 2026. https://priyalifescience.com/clinical-trials-europe/country/netherlands

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,777 trial records at the last sync on 06 Nov 2026, 03:17 UTC; this register shows the 2,556 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 97 of those trials with a site in Netherlands that also match the filters currently applied.

How many recently authorised EU trials have a site in Netherlands?

97 of the 2,556 most recently authorised trials in this register list a site in Netherlands and match the filters applied; 0 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (Netherlands), 97 trials
PhaseTrialsShare
Phase I97100%

Most active sponsors

Lead sponsors with the most trials (Netherlands)
Lead sponsorTrials
F. Hoffmann-La Roche AG7
Boehringer Ingelheim International GmbH4
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)4
Amsterdam UMC Stichting3
Novo Nordisk A/S3
Arvinas Operations Inc.2
Basilea Pharmaceutica International AG Allschwil2
Dompe' Farmaceutici S.p.A.2
Eli Lilly & Co.2
Genentech Inc.2
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.